Regulatory flexibility can make continuous improvement possible.
Tony Lubiniecki
Advertisement
Tony Lubiniecki is the vice president of biopharmaceutical development & marketed product support at Centocor R&D, Inc.
Articles by Tony Lubiniecki
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Advertisement
Latest Updated Articles
Quality by Design for Biotechnology Products—Part 3Published: January 1st 2010 | Updated:
Quality by Design for Biotechnology Products—Part 2Published: December 1st 2009 | Updated:
Quality by Design for Biotechnology Products—Part 1Published: November 1st 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Everything to Know About Cell and Gene Therapy in 2025
2
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
5
